Abstract:Malaria is an infectious disease that affects over 216 million people worldwide, killing over 445,000 patients annually. Due to the constant emergence of parasitic resistance to the current antimalarial drugs, the discovery of new drug candidates is a major global health priority. Aiming to make the drug discovery processes faster and less expensive, we developed binary and continuous Quantitative Structure-Activity Relationships (QSAR) models implementing deep learning for predicting antiplasmodial activity and cytotoxicity of untested compounds. Then, we applied the best models for a virtual screening of a large database of chemical compounds. The top computational predictions were evaluated experimentally against asexual blood stages of both sensitive and multi-drug-resistant Plasmodium falciparum strains. Among them, two compounds, LabMol-149 and LabMol-152, showed potent antiplasmodial activity at low nanomolar concentrations (EC50 <500 nM) and low cytotoxicity in mammalian cells. Therefore, the computational approach employing deep learning developed here allowed us to discover two new families of potential next generation antimalarial agents, which are in compliance with the guidelines and criteria for antimalarial target candidates.Malaria is a serious infectious disease caused by parasites of the genus Plasmodium. The recommended treatment is a combination of antimalarial drugs. However, the rise of parasites resistant to the current antimalarial drugs means that new therapeutics are continually required. To meet this challenge, we developed and applied models using deep learning, a powerful artificial intelligence method, supported by experimental validation to identify new drug candidates against malaria. We used the developed computational models to prioritize novel, active, and nontoxic compounds from virtual chemical libraries for experimental evaluation. Then, the predicted antimalarial compounds were experimentally validated in assays on Plasmodium falciparum culture. This allowed us to discover two new potential antimalarial candidates. The use of computational approaches is an attractive route to expedite the discovery of new therapeutics, especially to infectious tropical diseases, as it can reduce time and development costs. Future directions include in vivo studies on animal models.

Real-Time Imaging of Antimalarial Drug Effects on Plasmodium falciparum-Infected Red Blood Cells

Structure-Based Virtual Screening, Insilico Docking, ADME Prediction, and Molecular Dynamics Studies for Identification of Potential NMT Inhibitors Against Malaria

A high content imaging assay for identification of specific inhibitors of native Plasmodium liver stage protein synthesis

Mode of action of quinoline antimalarial drugs in red blood cells infected by Plasmodium falciparum revealed in vivo

Rapid and quantitative antimalarial drug efficacy testing via the magneto-optical detection of hemozoin

Kinetic Driver of Antibacterial Drugs against Plasmodium falciparum and Implications for Clinical Dosing

An all-in-one pipeline for the in vitro discovery and in vivo testing of Plasmodium falciparum malaria transmission blocking drugs

QSAR-Driven Design and Discovery of Novel Compounds With Antiplasmodial and Transmission Blocking Activities

On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

Development and Optimization of a Novel 384-Well Anti-Malarial Imaging Assay Validated for High-Throughput Screening

Deep Learning-driven research for drug discovery: Tackling Malaria

Exploration and Characterization of the Antimalarial Activity of Cyclopropyl Carboxamides that Target the Mitochondrial Protein, Cytochrome b

DeepMalaria: Artificial Intelligence Driven Discovery of Potent Antiplasmodials

Functional Phenotyping of MMV Pandemic Response Box Identifies Stage-specific inhibitors Against Blood stage Plasmodium

Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box

Real-time measurements of ATP dynamics via ATeams in Plasmodium falciparum reveal drug-class-specific response patterns

Autofluorescent antimalarials by hybridization of artemisinin and coumarin: in vitro/ in vivo studies and live-cell imaging

Natural Products for Treatment of Plasmodium Falciparum Malaria: an Integrated Computational Approach.

Towards development of new antimalarial compounds through in silico and in vitro assays

A non-traditional crystal-based compound screening method targeting the ATP binding site of Plasmodium falciparum GRP78 for identification of novel nucleoside analogues

Identification of novel antiplasmodial compound by hierarquical virtual screening and in vitro assays